NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.4 USD | -0.79% | -2.03% | +5.80% |
NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+5.80% | 14.03B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+28.03% | 11.67B | |
-31.18% | 7.55B |